Key Market Indicators
Norwegian antacid medicine sales are projected to reach $3 million by 2026. In 2021, sales totaled $3.5 million, a 1.9% decrease from the previous year. Over the past 14 years, the market has seen an average annual decrease of 0.8%. In 2021, Norway ranked 12th globally in antacid medicine sales. Finland took the top spot with $3.5 million in sales. Italy, Germany and Chile rounded out the top four, respectively.
